Cellect(QNRX) - 2025 Q4 - Annual Report

FDA Approval Process - On March 25, 2026, the FDA indicated that a single Phase 3 study may be sufficient for marketing approval of QRX003 in the U.S.[72] - The FDA approval process requires rigorous pre-clinical and clinical testing to demonstrate safety and effectiveness[92][98]. - The FDA requires two adequate and well-controlled Phase 3 clinical trials for prevalent diseases to demonstrate safety and efficacy[99]. - An NDA submission must include results from all pre-clinical and clinical testing, along with a substantial application user fee, which typically increases annually[101]. - The FDA's goal for acting on an NDA for a new molecular entity is ten months, but the preliminary review can extend this to twelve months[102]. - The FDA may issue a complete response letter (CRL) if the NDA has deficiencies, requiring the applicant to address these before resubmission[104]. - The FDA may require post-marketing studies to gather additional safety and efficacy data after NDA approval[122]. - The FDA may expedite the review of applications for products intended to treat serious or life-threatening conditions that show substantial improvement over existing therapies[112]. - Orphan drug designation provides a seven-year market exclusivity period for drugs treating rare diseases affecting fewer than 200,000 individuals in the U.S.[113]. Clinical Development - The first clinical site for QRX003 in pediatric patients with Peeling Skin Syndrome opened in December 2024, with significant improvements observed after 12 weeks of treatment[75][76]. - Quoin plans to submit a pre-IND meeting request for QRX009 by the end of Q2 2026 and initiate clinical testing in Proof of Concept studies before the end of 2026[77]. - QRX003 has the potential to be the first approved treatment for NS globally, with plans for self-commercialization in the U.S., Western Europe, and Japan[78][79]. Market and Competition - The company has established nine marketing partnerships for QRX003 covering 61 countries, including Australia, New Zealand, and major Latin American countries[79]. - The company faces competition from other biotechnology firms and research institutions, with several candidates for NS treatment currently in development[84]. - Direct or indirect governmental price regulation may affect the prices charged for product candidates, with ongoing legislative proposals that could significantly impact the pharmaceutical industry[128]. - The Inflation Reduction Act requires the U.S. Department of Health and Human Services to negotiate prices for certain drugs, with the first negotiated prices taking effect in 2026 for 10 high-cost Medicare Part D products[130]. Financial and Regulatory Considerations - A formal pricing analysis for QRX003 has not been concluded, with anticipated influences from FDA negotiations and pharmacoeconomic data[83]. - The ability to commercialize product candidates depends significantly on adequate financial coverage and reimbursement from third-party payors, with significant uncertainty regarding insurance coverage for newly approved products[127]. - The company anticipates ongoing legislative and regulatory interest in drug pricing practices, which may lead to further reductions in coverage and reimbursement levels for pharmaceutical products[129]. - The company is subject to various global privacy and data protection laws, which could result in significant penalties and reputational harm if not complied with[126]. Company Structure and Operations - The company had four full-time employees and two part-time employees as of December 31, 2025, with no collective bargaining agreements in place[136]. - The company is classified as a "smaller reporting company," allowing it to take advantage of reduced disclosure obligations under the Securities Exchange Act[146]. - The company completed a business combination with Quoin Pharmaceuticals, Inc. on October 28, 2021, and subsequently changed its name to Quoin Pharmaceuticals Ltd.[142]. - The company is obligated to file reports with the SEC as a U.S. domestic issuer since January 1, 2023, which requires more detailed disclosures than those for foreign private issuers[142]. - The company’s operations do not produce hazardous waste, and it is not subject to hazardous materials regulations[134]. - The company is classified as a smaller reporting company under Rule 12b-2 of the Exchange Act and is not obligated to provide the disclosures typically required under Item 7A[369]. Intellectual Property and Confidentiality - The company entered into a License Agreement with Skinvisible Pharmaceuticals, paying a one-time fee of $1 million and agreeing to a royalty percentage on net sales[89]. - Quoin relies on trade secret protection and confidentiality agreements to safeguard proprietary know-how not covered by patents[90].